RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the biochemical response rate (PSA) to single agent
RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).